Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02158052 · ClinicalTrials.gov registry record · NA
Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT02158052: Completed NA study, sponsored by Massachusetts General Hospital.
NCT02158052 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02158052, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
This pilot trial offers the unique opportunity for both the treatment of multiple myeloma or systemic AL amyloidosis for which hematopoietic stem cell transplantation would be ordinarily indicated and the reversal of end-stage renal failure, while avoiding the risks associated with long-term standard anti-rejection therapy used in renal transplantation. The primary objectives of this study are to assess renal allograft tolerance (that is, the acceptance of the kidney without the need for anti-rejection therapy), assess anti-tumor response rates in multiple myeloma and AL amyloidosis, and assess complication rates for genetically (HLA) matched related donor combined bone marrow and kidney transplantation using a low dose total body irradiation based preparative regimen.
Interventions
- DRUG Tacrolimus
- DRUG Equine Anti-thymocyte globulin
- PROCEDURE Kidney transplant from a related donor
- DRUG Bone marrow transplant from a related donor
- RADIATION Total body irradiation 400 centigray (200 cGy X 2)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2015-02 |
| Est. Completion | 2021-06-22 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02158052
The ClinicalTrials.gov registry entry for NCT02158052 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Tacrolimus is the first listed.
NCT02158052 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02158052 about?
NCT02158052 is a clinical study titled "Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease". This pilot trial offers the unique opportunity for both the treatment of multiple myeloma or systemic AL amyloidosis for which hematopoietic stem cell transplantation would be ordinarily indicated and the reversal of end-stage renal failure, while avoiding the risks associated with long-term standar...
What is the current status of trial NCT02158052?
This trial is currently completed. It is a NA study. The enrollment target is 2 participants. The study started on 2015-02. Estimated completion is 2021-06-22.
What interventions are being tested in trial NCT02158052?
The interventions under investigation include: Tacrolimus (DRUG), Equine Anti-thymocyte globulin (DRUG), Kidney transplant from a related donor (PROCEDURE), Bone marrow transplant from a related donor (DRUG), Total body irradiation 400 centigray (200 cGy X 2) (RADIATION).
Who is sponsoring clinical trial NCT02158052?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.